Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug
1. Pfizer has a $6 billion licensing deal with 3SBio Inc for cancer treatment. 2. The partnership focuses on drug development for specific cancer types and tumors.
FAQ
Why Bullish?
This deal diversifies Pfizer's oncology portfolio, similar to past successful collaborations (e.g., with BioNTech). Licensing revenues could enhance PFE's growth profile substantially.
How important is it?
The licensing deal may provide essential revenue and broaden Pfizer's market in oncology, influencing its overall valuation positively.
Why Long Term?
Successful development could lead to significant revenue streams over several years, similar to trends seen with cancer treatments like Keytruda.